Beyond Weight Loss: A New Drug Targets Fatty Liver Disease Directly

I recently discussed how the ESSENCE trial showed that semaglutide can reverse liver fibrosis, not just fat, in patients with metabolic dysfunction-associated steatohepatitis (MASH). That drug, like most current options, works largely by driving weight loss, which secondarily improves the liver. A new experimental therapy, ION224, takes a genuinely different approach: it targets a specific enzyme in the liver itself, and its Phase IIb results suggest it can improve liver health even in patients who do not lose significant weight — a distinction that matters for how we think about treating this disease going forward.

What MASH is, briefly

MASH (metabolic dysfunction-associated steatohepatitis, previously known as NASH) is the more aggressive form of fatty liver disease, in which excess fat in the liver is accompanied by inflammation and, over time, scarring (fibrosis) that can progress to cirrhosis and liver cancer. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome, and it has become one of the most common reasons patients are referred to me for liver evaluation and, in advanced cases, transplant assessment.

How ION224 works

ION224 is an antisense oligonucleotide — a lab-designed strand of genetic material that blocks the liver from producing a specific protein — in this case, DGAT2, an enzyme that plays a central role in how liver cells manufacture and store fat. By reducing DGAT2 activity, the drug directly interrupts the process by which fat accumulates and drives inflammation inside liver cells, rather than relying on appetite suppression and calorie reduction to indirectly relieve the liver of fat. This is a meaningfully different mechanism from GLP-1 drugs, and it opens the door to combination approaches down the line.

What the trial showed

In a Phase IIb trial of 160 participants in the United States followed for 51 weeks, roughly 60% of patients receiving the highest tested dose showed meaningful improvement in liver health measures compared to placebo, with no serious drug-related adverse events reported. The detail I find most clinically interesting is that liver improvement was observed even among patients who did not lose substantial body weight — the first clear demonstration that blocking DGAT2 through this antisense approach can reduce liver inflammation and fibrosis somewhat independently of weight loss.

Why this distinction matters

Not every patient with MASH tolerates or responds fully to GLP-1-based therapy, and not every patient's liver disease improves in lockstep with their weight loss — some patients lose significant weight with comparatively modest liver improvement, and clinicians have long suspected that liver-specific mechanisms, separate from systemic weight change, are also at play. A drug that improves the liver through a distinct pathway raises the realistic possibility of future combination therapy: using a GLP-1-based drug to address weight, cardiovascular risk, and appetite, alongside a liver-targeted agent like ION224 to address fat accumulation and inflammation directly within liver cells — potentially producing better outcomes than either mechanism alone, particularly in patients whose liver disease is more advanced relative to their body weight.

What stage this treatment is at

I want to set expectations clearly: this is Phase IIb data, in a relatively small population (160 patients), and Phase III trials — larger, longer, and required for approval — have not yet reported. Antisense oligonucleotide drugs, as a class, also typically require subcutaneous injection on a periodic schedule, an important practical consideration for patients weighing treatment options. As with any early-stage trial, real-world durability, long-term safety, and performance in a broader, more diverse patient population remain to be established.

What I tell my patients

If you have MASH, current evidence-based treatment still centers on weight loss through lifestyle changes, and where appropriate, GLP-1-based medication or, in the right candidates, bariatric surgery — approaches with a much larger and more mature evidence base than ION224 currently has. But it is genuinely encouraging to see a mechanistically distinct drug show liver benefit independent of weight loss, because it suggests the field is moving toward a future with multiple, complementary tools rather than a single approach for a disease that varies considerably from patient to patient. I will continue to follow this drug's development and update patients as Phase III data become available.

Source: Ionis Pharmaceuticals Phase IIb trial of ION224 (DGAT2-targeted antisense therapy) in MASH (2026).